Navigation Links
New Drug Delivery System to Improve Cancer Treatment

SYRACUSE, N.Y., March 16, 2011 /PRNewswire/ -- Scientists in Syracuse University's Chemistry Department have created a new drug delivery system expected to advance the effectiveness of cancer-killing drugs. It uses gold nanoparticles with attached DNA that binds to a proven anti-cancer drug, Doxorubicin or DOX.

Preliminary tests indicate this delivery device has the potential to significantly improve the results of cancer chemotherapy. DOX is currently used against cancers of the breast, bone marrow, thyroid, bladder, ovary, small cell lung and several others.

"The possibilities of this new system are really exciting," says SU Professor James C. Dabrowiak. "For example, it would be easy to add to the device molecules that have the ability to target cancer cells. Another possibility is using light excitation to release high concentrations of an anti-tumor drug directly within the tumor."

These and other upgrades could enable clinics to focus chemotherapy more tightly on cancer cells and reduce negative side effects on healthy cells in other parts of the body.

A key element of the new system is that the DNA attached to the gold particles is engineered specifically to bind to the DOX anti-tumor drug. Studies show that the DOX can be transferred by diffusion to a receptor DNA molecule.

The gold nanoparticles have an average diameter of only 15.5 nanometers or a few billionths of a meter. A single nanoparticle presents more than 100 DOX sites and that, when multiplied by millions of the particles, could create a massive and deadly assault on a tumor.

"We believe this work can bring significant gains in the effectiveness of chemotherapy treatments," says Mathew M. Maye, SU Assistant Professor of Chemistry and co-inventor of the delivery system. "We still have work to do but this advance opens a promising new field of investigation that can lead to important new clinical tools."

A key advantage of the new system is that the DOX anti-tumor drug is already accepted by the FDA. Other such drugs may be deployed using this system simply by engineering the DNA to bind to a different drug molecule.

The Syracuse laboratory is continuing investigations to check the toxicity of the system. They will also explore "smart" particles capable of attaching to cancer cells and responding to triggers that will activate drug release. Prior discoveries demonstrate that such nano-delivery systems may be within reach and could help deliver large payloads of anti-tumor drugs where needed.

Graphic: Attacking Cancer with Tiny Drug Carriers

The work of the Syracuse University team was published in a February 2011 issue of ChemComm, a publication of the Royal Society of Chemistry. For more information and access to explanatory graphics, call (315) 443-4601 / 443-2146 or e-mail / mmmaye@syr.eduFor information, contact: Prof. James C. Dabrowiak(315) 443-4601 Mathew M. Maye(315) 443-2146 mmmaye@syr.eduThis press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE Syracuse University Office of Technology Transfer and Industrial Development
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spherics, Inc. Offers Once Daily Extended Release Formulation for Sustained and Stable Pramipexole Delivery
2. Spherics, Inc. Announces Sale of Novel Proprietary Bioadhesive Polymers and Oral Drug Delivery System
3. Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
4. CEL-SCI Takes Delivery of New Manufacturing Facility
5. Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care
6. MonoSol Rx and Midatech Group Enter Collaboration Agreement to Unite Nanoparticle and Thin Film Drug Delivery Technologies
7. Probiotic Delivery Technology Awarded Third International Patent
8. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
9. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
10. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
11. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
Post Your Comments:
(Date:11/26/2015)... , England , November 26, 2015 ... Lightpoint Medical, an innovative medical device company specializing in imaging ... grant from the European Commission as part of the Horizon ... the company to carry out a large-scale clinical trial in ... -->      (Logo: , --> ...
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
Breaking Biology News(10 mins):